Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, Pharmacokinetics, and Food Effect of BI 3000202 in Healthy Male Subjects
NCT05945888Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3000202 (10 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Any Treatment-emergent Adverse Event Assessed as Drug-related by the Investigator up to 2 days, Area Under the Concentration-time Curve of BI 3000202 in Plasma Over the Dosing Interval 0 to 24 Hours and 1 more. Started Jul 2023; status: completed.
02
Drugs
BI 3000202
Beyond the preview
Go deeper on NCT05945888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945888.